Kazia Therapeutics Limited (KZIA) 6-K/A Current report (foreign) (amended)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington. D.C. 20549

Form 6-K/A
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of                   March     , 2003

Novogen Limited

(Translation of registrant’s name into English)

140 Wicks Road, North Ryde, NSW, 2113, Australia

(Address of principal executive office)

[Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F þ    Form 40-F o

[Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes o    No o

[If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2 (b):
82- ___________.1

SEGMENT INFORMATION — PRIMARY SEGMENT

	Australia/NZ						North America						Europe						Elimination						Consolidated
	2002			2001			2002			2001			2002			2001			2002			2001			2002			2001
	$'000			$'000			$'000			$'000			$'000			$'000			$'000			$'000			$'000			$'000
Geographical Segments
Revenue
Sales to customers outside the consolidated entity		3,306			2,390			6,168			6,457			1,392			1,396			—			—			10,866			10,243
Other revenues from customers outside the consolidated entity		2,964			2,643			293			261			—			—			(123	)		—			3,134			2,904
Intersegment Revenues		3,493			2,007			8			143			—			—			(3,501	)		(2,150	)		—			—
Total segment revenue		9,763			7,039			5,470			6,861			1,392			1,396			(3,624	)		(2,150	)		14,000			13,146
Unallocated revenue																										663			672
Total Consolidated Revenue																										14,663			13,819
Results
Segment result		(949	)		(3,472	)		(2,295	)		(4,668	)		(1,023	)		(1,157	)		110			2,300			(4,157	)		(6,997	)
Unallocated expenses																										(71	)		(163	)
Consolidated entity profit from ordinary activities before income tax																										(4,228	)		(7,161	)
Income tax expense																										—			(40	)
Net profit																										(4,228	)		(7,201	)

	Australia/NZ						North America						Europe						Elimination						Consolidated
	2002			2001			2002			2001			2002			2001			2002			2001				2002			2001
	$'000			$'000			$'000			$'000			$'000			$'000			$'000			$'000			$'000				$'000
Geographical Segments
Assets
Segment assets		97,481			103,777			22,212			9,438			1,788			1,687			(63,777	)		(62,253	)			57,704			52,649
Liabilities
Segment Liabilities		(11,072	)		(11,851	)		(51,268	)		(56,654	)		(10,555	)		(9,319	)		68,077			69,380				(7,818	)		(7,944	)
Other segment information
Acquisition of property plant and equipment, intangible assets and other non current assets		126			136			27			41			4			12			—			—				157			189
Depreciation		56			460			24			60			6			6			—			—				591			527
Amortisation		237			393			—			—			—			—			16			16				253			409
Non cash expenses other than depreciation and amortisation		70			736			351			172			(1	)		80			35			—				455			987

Note:

The Novogen Group operates subsidiary companies in 3 major geographical areas being Australia/New Zealand, North America including the USA and Canada and Europe including the UK and the Netherlands. The subsidiaries are all involved in the selling and marketing of Novogen’s dietary supplements including Promensil, Trinovin and Rimostil. The US company is also responsible for manufacturing and packaging products for the domestic US market. The other countries products are supplied from Australia in fully finished form.

All of the Group’s sales revenues are sales of Novogen’s dietary supplements. The Novogen Group operates in one business segment being to manufacture, market and sell dietary supplements.

SEGMENT INFORMATION — SECONDARY SEGMENT

					Pharmaceutical
	Dietary Supplements				Research &				Elimination						Consolidated
					Development
	2002		2001		2002		2001		2002			2001			2002		2001
	$'000		$'000		$'000		$'000		$'000			$'000			$'000		$'000
Segment Revenue		12,052		13,057		2,611		762		—			—			14,663		13,819
Segment Assets		100,168		132,951		21,313		1,327		(63,777	)		(81,628	)		57,705		52,649
Acquisition of property plant and equipment, intangible assets and other non current assets		131		57		26		132		—			—			157		189

Six Months Ended December 2002 — Earnings Per Share

	Current			Previous
	Period			Corresponding
				Period
	$'000			$'000
The following reflects the income and share data used in calculating basic and diluted earnings per share
Net Loss		(4,228	)		(7,201	)
Adjustments:
Net loss attributable to outside equity interests		(107	)		—
Earnings used in calculating basic and diluted earnings per share		(4,121	)		(7,201	)

	Number of Shares			Number of Shares
Weighted average number of ordinary shares used in calculating basic and dilutive earnings per share		95,417,266			95,069,775
Basic loss per share — (cents)		(4.3	)		(7.6	)
Diluted loss per share — (cents)		(4.3	)		(7.6	)

Diluted earnings per share:

The notional issue of potential ordinary shares of 1,100,706 outstanding options exercisable at 31 December 2002 does not result in diluted earnings per share that shows an inferior view of the earnings performance of the Company, therefore the information has not been disclosed

Conversions, call subscriptions or issues after 31 December 2002.

There have been 22,871 conversions of or subscriptions for ordinary shares or issues of potential ordinary shares since the reporting date and before the completion of this financial report.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Novogen Limited       (Registrant)
Date        5 March, 2003	By	/s Ronald Lea Erratt
		Ronald Lea Erratt Company secretary